Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive condition that can be caused by genetic mutations or aging, and is characterized by accumulating heart damage that ultimately leads to symptoms of heart failure. In ATTR-CM,…
The most common signs of transthyretin amyloid cardiomyopathy (ATTR-CM) are those typically associated with heart failure, although problems in the nervous system or other tissues can also occur. ATTR-CM is a type of cardiac amyloidosis,…
A diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) is typically reached through a series of tests to identify signs of the disease and rule out related disorders. ATTR-CM is a type of heart amyloidosis, a group…
The treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) is a multidisciplinary effort involving interventions to slow disease progression and manage symptoms. ATTR-CM is a form of amyloidosis, where protein clumps, called amyloid deposits, accumulate in tissues.
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a form of heart disease that’s typically caused by genetic mutations or aging. Determining the root cause of ATTR-CM can help guide treatment decisions, understand prognosis, and determine if family…
Latest News & Community Perspectives
Discussion
Regulatory authorities in the European Union (EU) have recommended approval of Tafamidis Accord, a generic version of Vyndaqel (tafamidis), an approved treatment for adults with hereditary transthyretin amyloid cardiomyopathy (hATTR-CM). A generic medicine has the…
Discussion
Women with transthyretin amyloid cardiomyopathy (ATTR-CM) had worse outcomes than men in a new study, but the gap may reflect differences in age and disease severity at diagnosis rather than biological sex alone. Researchers…
Discussion
A type of cell damage called oxidative stress may be key to the development of disease symptoms in people who carry the most common TTR gene mutation that causes hereditary transthyretin amyloidosis with polyneuropathy…
Discussion
Long-term treatment with the experimental therapy candidate cliramitug safely and effectively reduces toxic clumps of the transthyretin (TTR) protein and heart damage markers in adults with transthyretin amyloid cardiomyopathy (ATTR-CM). That’s according to…
Discussion
The injectable therapy eplontersen failed to show a significant benefit over a placebo at reducing cardiovascular events and related deaths in a Phase 3 clinical trial of adults with transthyretin amyloid cardiomyopathy (ATTR-CM).
Discussion
Amvuttra (vutrisiran) rapidly and consistently reduces blood levels of transthyretin (TTR), the disease-causing protein in hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), across a wide range of patients, according to clinical trial data. Similar…
Discussion
Attruby (acoramidis), an approved therapy for transthyretin amyloid cardiomyopathy (ATTR-CM), may help preserve kidney function in adults with the rare heart disease, potentially lowering their risk of early cardiovascular events, according to a…
Discussion
Collecting and analyzing wrist tissue for the presence of hallmark toxic protein clumps may not be sufficient as a stand-alone strategy for early detection of transthyretin cardiac amyloidosis (ATTR-CM) in African Americans undergoing surgery…
Discussion
For East Asian adults with transthyretin amyloid cardiomyopathy (ATTR-CM), the approved therapy Amvuttra (vutrisiran) is a safe and effective treatment, with significant long-term benefits. Those are the findings of a new data analysis…
Discussion
People carrying the p.V142I mutation in the TTR gene — which is mostly associated with hereditary transthyretin amyloid cardiomyopathy (hATTR-CM) — often have polyneuropathy, or damage to multiple nerves, a U.S. study shows. But…